Navigation Links
Anesiva Outlines Comprehensive Commercialization Plan for FDA Approved Product Zingo(TM)
Date:10/12/2007

ction capacity for Zingo while

reducing the manufacturing cost of goods for the product at minimal

additional capital expense.

Commercial quantities of Zingo, which was approved by the FDA in August, are expected to be available in the second quarter of 2008. Today's briefing reviewing Anesiva's commercialization plans will be webcast and may be found at http://www.anesiva.com In addition to the live webcast, a replay will be available.

"Blood draws and intravenous access procedures are a huge source of anxiety and stress for children and their parents. Despite published guidelines calling for the use of topical local anesthetics during these procedures, currently existing topical anesthetic creams and patches are not routinely used because they take 20 minutes or longer to act," stated William T. Zempsky, M.D., associate professor, Department of Pediatrics, University of Connecticut; associate director, Pain Relief Program, Connecticut Children's Medical Center, Hartford. "Zingo's rapid onset means that it can be easily incorporated into a medical procedure allowing uninterrupted care, an important advantage over current options." Dr. Zempsky will be the featured speaker at today's briefing.

"We are very excited about the prospects for Zingo, given its outstanding profile and the significant interest we have received from the public and from the medical community since the product received early FDA approval in August," stated John P. McLaughlin, chief executive officer of Anesiva. "We are maximizing the time until product availability with significant efforts to build advocacy and making the need to treat IV pain top of mind among targeted customers. This is intended to expedite Zingo's acceptance on hospital formularies and drive routine use. The collaboration we are announcing today with Sagent will support these efforts by enabling us to rapidly ramp up sales and ultimately
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Doyle outlines spending for Medical College, UWM
2. Kanavas outlines new Invest Wisconsin agenda
3. UW stem cell guru outlines scientific and political future
4. Three Wisconsin approaches to technology transfer and commercialization
5. Medical College gets support to expand technology commercialization
6. Genzyme acquistion of Bone Care approved, significant impact forecast
7. A New C-Terminal GST Vector for Protein Production in S. pombe
8. Safe Production of High-Titer Retrovirus
9. Production of Full-Length, Biologically Active MEK1WT and MEK1CA
10. Yeast Protein Production System Features High Yields and One-Step Purification
11. Identification of Differentially Expressed Gene Products with the CastAway System*
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Aug. 27, 2014  ARCH Venture Partners, one ... in the development of seed and early-stage advanced ... fund closed with more than $400 million in ... million subscription target by more than $150 million. ... the strength and potential of our approach to ...
(Date:8/27/2014)... August 27, 2014 After the boom ... that the next beverage craze is going to be ... that formulators can use Stress Relief energy pattern which ... the making of a beverage, including minerals, herbs and ... energy, channeling that power into rapid recovery and helping ...
(Date:8/27/2014)... Budding Biomedical Scientists , This ... participated in the Scientific Enrichment and Opportunity ... of Medicine . , The rigorous ... experience in the sciences and brings them in ... students for both academic and career mentoring. , ...
(Date:8/26/2014)... An analysis by Replikins, Ltd. of Pubmed data of ... virus strains has revealed extensive conservation and sharing of ... sharing of specific Replikin gene structures has permitted the ... did for the H5N1 influenza vaccine and the Taura ... to be effective (1,2). This ...
Breaking Biology Technology:Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 2Stress Relief: 1 Way to De-Stress Your Beverage Formula 3Stress Relief: 1 Way to De-Stress Your Beverage Formula 4Students at Cleveland's University School Conduct Biomedical Research at Case Western Reserve University’s School of Medicine 2
... NEW YORK and MONTREAL, Dec. 21 /PRNewswire-FirstCall/ - ICBS Ltd. ... state and municipal regulatory bodies for the sale of the ... Solutions will be moving to target regulatory agencies in the ... advantages not only on time advantage (10 Hours for test ...
... III trials of OGX-011 in first- and second-line advanced ... begin in 2010 and early 2011 -- , -- ... to target resistance to cancer treatments -- , JERUSALEM, ... - Teva Pharmaceutical Industries Ltd. ( TEVA) and OncoGenex ...
... , , THOUSAND OAKS, Calif., Dec. ... Roger M. Perlmutter, M.D., Ph. D., Amgen,s executive vice ... Fellow of the American Association for the Advancement of Science ... on behalf of the advancement of science or its applications ...
Cached Biology Technology:BioSpec Global Solutions Inc. target market TOGS 9000 to state and municipal regulatory bodies in U.S. market 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 2Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 3Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 4Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 5Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 6Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 7Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications 8Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 2Amgen's Roger M. Perlmutter, M.D., Ph.D., Named 2009 AAAS Fellow, Recognized for Discovery, Development of Novel Medicines 3
(Date:8/27/2014)... as giant, frightening beasts. But every creature is a ... slab containing fossils of 24 very young dinosaurs and ... hatchlings overseen by a caretaker, according to a new ... P. Hedrick and Peter Dodson led the work, collaborating ... where the specimen is held. Hedrick is a doctoral ...
(Date:8/27/2014)... that a deficiency in serotonin a chemical messenger ... depression. In the journal ACS Chemical Neuroscience , ... serotonin in their brains (and thus should have been ... , Donald Kuhn and colleagues at the John ... School of Medicine note that depression poses a major ...
(Date:8/27/2014)... have shown that excessive iron is closely ... Previous studies from Chunyan Guo and co-workers ... shown that baicalin prevented iron accumulation after ... 1 expression, and increased ferroportin 1 expression ... disease rats. However, the relationship between iron ...
Breaking Biology News(10 mins):Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 2Penn paleontologists describe a possible dinosaur nest and young 'babysitter' 3New study throws into question long-held belief about depression 2
... at the U.S. Department of Energy,s Lawrence Berkeley National ... into wispy nanoscale ropes that approach the structural complexity ... development in the push to develop self-assembling nanoscale materials ... but which are rugged enough to withstand harsh conditions ...
... Energy,s Pacific Northwest National Laboratory has been recognized for ... The award-winning partnerships are helping analyze trace amounts of ... and more easily study live cells., The Federal Laboratory ... 2011 for Excellence in Technology Transfer. The consortium is ...
... have proven that you don,t have to travel to exotic ... distinctive species of crayfish in Tennessee and Alabama that is ... genetic relative, once thought to be the only species in ... in Kentucky, can grow almost as big as a lobster. ...
Cached Biology News:A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 2A nanoscale rope, and another step toward complex nanomaterials that assemble themselves 3PNNL recognized for technology transfer 2PNNL recognized for technology transfer 3Researchers discover giant crayfish species right under their noses 2Researchers discover giant crayfish species right under their noses 3Researchers discover giant crayfish species right under their noses 4
Human endothelial progenitor cells, For immunohistochemistry (IHC) Cell Chip with Human Peripheral Blood Dendritic Cells and EPCs...
Plasmacytoid dendritic cells, BDCA-4+, For immunohistochemistry (IHC) Cell Chip with Human Umbilical Cord Blood Dendritic Cells...
...
...
Biology Products: